Phase 4 N=71 A Pilot Study of Dexmedetomidine-Propofol in Children Undergoing Magnetic Resonance Imaging
Epilepsy · Cerebral Palsy · Developmental Delay
Primary: Dosage/Consumption — 0.36; 0.25 mcg/kg/min
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=13 Add-on Peginterferon Following Nucleos(t)Ide Analogue Treatment
Chronic Hepatitis B
Primary: Change in Interferon-stimulated-gene (ISG) Expression — -2.716; 1.670; -2.20; -1.597 log 2 fold change
N/A N=84 Decreasing Postoperative Pain Following Endometrial Ablation
Postoperative Pain
Primary: Postoperative Pain Score — 2.71; 1.44; 3.37; 2.81 units on a scale
N/A N=300 Collaborative Connected Health (CCH) for PCORI
Psoriasis
Primary: Improvement in Self-Administered Psoriasis Area and Severity Index (SA-PASI) — -0.82; -1.37 Score on a Scale
Phase 2 N=14 Phase 2 Study With SNF472 in Calciphylaxis Patients
Calciphylaxis · Calcific Uremic Arteriolopathy
Primary: Wound Healing — -8.1 units on a scale — p=<0.001
Phase 2 N=65 Clinical Trial of Ezogabine (Retigabine) in ALS Subjects
Amyotrophic Lateral Sclerosis
Primary: Change in Short-interval Intracortical Inhibition (SICI) Measured by Transcranial Magnetic Stimulation (TMS) — 1.180; 0.965; 0.784; 1.347 Unitless
Phase 2 N=53 Pharmacogenetic Trial of Tacrolimus After Pediatric Transplantation
Heart Transplantation · Liver Transplantation · Kidney Transplantation
Primary: Time to Achieve Therapeutic Tacrolimus Drug Concentrations — 4.7; 3.4 Days
Phase 3 N=306 Study to Assess the Tolerability and Efficacy of Anacetrapib (MK-0859) Co-Administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020)
Hyperlipoproteinemia Type II · Hypercholesterolemia, Familial
Primary: Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) - Treatment Phase — -36.0; 3.7 Percent Change — p=<0.001
Phase 2 N=133 A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor
Lung Cancer, Non-Small Cell
Primary: Time to Occurrence of Any Recurrence of Disease — 0.217; 0.067 person-year rate — p=0.1422
Phase 3 N=1,254 An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine
Migraine, With or Without Aura
Primary: Percentage of Participants With at Least 1 Treatment Emergent Adverse Event — 65; 66.3; 72.6 Percentage of Participants
Phase 3 N=1,890 Efficacy and Safety of Subcutaneous Administration of Fremanezumab (TEV-48125) for the Preventive Treatment of Migraine
Migraine
Primary: Number of Participants With Adverse Events (AEs) — 365; 456; 365; 426 Participants
N/A N=12 Walk Assist Device to Improve Community Ambulation
Stroke
Primary: Change in Six Minute Walk Test Between Device Turned ON and OFF - Distance Traveled — 837.1; 804.8 feet
N/A N=161 Acupuncture and Nausea/Vomiting in Pediatric Patients
Postoperative Vomiting and Nausea
Primary: Postoperative Nausea and Vomiting — 26; 6; 37; 31 Participants
N/A N=30 A Pilot Study to Assess Nominal Versus Controlled Stimuli on Dentinal Hypersensitivity
Dentin Sensitivity
Primary: Change From Baseline for Visual Analog Scale - Cold Water — -22.93 Units on a scale
Phase 3 N=84 Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma
UC (Urothelial Cancer)
Primary: Objective Response Rate (ORR) With Pembrolizumab + Epacadostat Versus Pembrolizumab + Placebo — 21.4; 9.5 percentage of participants